BioNTech has held confidential discussions with prospective bidders regarding plans to shutter manufacturing locations in Germany, Handelsblatt reported. The company announced with its first-quarter 2026 results that it would exit its German manufacturing sites in Idar-Oberstein, Marburg, and Tübingen by the end of this year as part of a restructuring to optimize global production capacity. It also plans to exit its unprofitable unit JPT Peptide in Berlin by year-end, with a search for a new peptide supplier already underway. The divestments come as BioNTech grapples with a sharp revenue decline, from 21.6 billion dollars in 2021 to 3.4 billion dollars in 2025, due to plummeting demand for its Comirnaty COVID-19 vaccine developed with Pfizer.
BioNTech SEPlummeting demand for Comirnaty COVID-19 vaccine drives revenue decline and site closures.
Pfizer Inc